OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
CTE55

Cryosite Ltd

Healthcare Facilities & ServicesVerified

Cryosite operates with a fully diluted share count of 48.81 million shares, with no additional shares outstanding in the diluted count, indicating no dilution from stock options or convertible instruments. However, the company's liquidity position could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents, which raises uncertainty about its short-term financial flexibility. Profitability and return metrics are not available for Cryosite, as the valuation snapshot does not include key performance indicators such as ROIC, EBITDA margins, or net profit margins. This lack of data makes it difficult to assess the company's efficiency and returns relative to industry peers or the preferred metrics outlined in the industry configuration. Cryosite's revenue is primarily derived from its core cryogenic storage and logistics services, with no disclosed segment or geographic breakdown in the available data. This lack of segmentation detail limits the ability to assess revenue concentration or geographic diversification. The company's growth trajectory is also unclear, as the outlook section does not provide numeric deltas or forward-looking revenue guidance for the current or next fiscal year. Without historical revenue data or forward-looking statements, it is difficult to determine whether the company is in a growth or contraction phase. Risk factors for Cryosite include the inability to assess liquidity risk, which could impact its ability to meet short-term obligations. The company is also exposed to dilution risk, though it is currently rated as low. No specific dilution sources or adjustments have been identified in the valuation data. Recent events or filings have not been disclosed in the available data, which limits the ability to assess any material developments or strategic shifts in the company's operations or financial position.

30-day price · CTE-0.09 (-8.7%)
Low$1.00High$1.16Close$1.00As of17 May, 00:00 UTC
Profile
CompanyCryosite Ltd
TickerCTE.AX
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Cryosite Ltd provides cryogenic storage and logistics solutions for the biotechnology and healthcare industries, primarily generating revenue through storage fees and service contracts.

Classification. Cryosite is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a high confidence level of 0.92 based on verified market data.

Cryosite operates with a fully diluted share count of 48.81 million shares, with no additional shares outstanding in the diluted count, indicating no dilution from stock options or convertible instruments. However, the company's liquidity position could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents, which raises uncertainty about its short-term financial flexibility. Profitability and return metrics are not available for Cryosite, as the valuation snapshot does not include key performance indicators such as ROIC, EBITDA margins, or net profit margins. This lack of data makes it difficult to assess the company's efficiency and returns relative to industry peers or the preferred metrics outlined in the industry configuration. Cryosite's revenue is primarily derived from its core cryogenic storage and logistics services, with no disclosed segment or geographic breakdown in the available data. This lack of segmentation detail limits the ability to assess revenue concentration or geographic diversification. The company's growth trajectory is also unclear, as the outlook section does not provide numeric deltas or forward-looking revenue guidance for the current or next fiscal year. Without historical revenue data or forward-looking statements, it is difficult to determine whether the company is in a growth or contraction phase. Risk factors for Cryosite include the inability to assess liquidity risk, which could impact its ability to meet short-term obligations. The company is also exposed to dilution risk, though it is currently rated as low. No specific dilution sources or adjustments have been identified in the valuation data. Recent events or filings have not been disclosed in the available data, which limits the ability to assess any material developments or strategic shifts in the company's operations or financial position.
Key takeaways
  • Cryosite operates in the Healthcare Facilities & Services industry, providing cryogenic storage and logistics solutions.
  • The company's liquidity position could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
  • Profitability and return metrics are not available, making it difficult to evaluate performance relative to industry benchmarks.
  • No segment or geographic revenue breakdown is provided, limiting visibility into revenue concentration and diversification.
  • Growth trajectory and forward-looking guidance are not disclosed, making it challenging to assess future performance.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyAUD
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$10.0M$1.2M$652.6k$844.8k
FY-3$11.8M$1.9M$1.4M$1.1M
FY-2$11.9M$1.5M$1.4M$1.3M
FY-1$12.6M$2.1M$1.8M$1.4M
FY0$14.1M$2.5M$1.9M$1.2M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$22.0M$377.5k$3.9M
FY-3$21.5M$1.9M$5.3M
FY-2$22.6M$2.8M$5.7M
FY-1$19.7M$1.4M$0.00
FY0$19.5M$2.4M
PeriodOCFCapExFCFSBC
FY-4$515.4k-$396.9k$844.8k
FY-3$2.5M-$863.2k$1.1M
FY-2$1.4M-$301.0k$1.3M
FY-1$2.7M-$452.0k$1.4M
FY0$2.1M-$586.0k$1.2M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Biotechnology · cohort 117 companies
MetricCTEActivity
Op margin5.6% medp25 -4.2% · p75 12.6%
Net margin2.8% medp25 -3.4% · p75 8.8%
Gross margin36.5% medp25 23.7% · p75 65.2%
CapEx / revenue-4.9% medp25 -11.5% · p75 -2.0%
Debt / equity69.3% medp25 7.9% · p75 120.9%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-09 06:00 UTC#1207a979
Market quoteclose AUD 1.00 · shares 0.05B diluted
no public URL
2026-05-09 06:00 UTC#7f2fd2fe
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 17:21 UTCJob: 540cea06